Richard Bax

Senior Partner

Richard is a key tranScrip expert in Infectious Diseases and has been involved in many clinical development programmes and regulatory submissions. He has over 38 years of industry experience, including working for Glaxo, Lilly and Astra Zeneca and has developed many antibiotics and antivirals.

Richard was VP at SmithKline Beecham from 1991-1999, working in London and Philadelphia, in charge of Global Anti-infective Clinical Development, resulting in over 15 successful NDAs /MAAs and launches including Famvir/penciclovir, Bactroban and Augmentin BD. Between 2000 and 2003, Richard was Chief Scientist to Biosyn, a microbicide company based in Philadelphia. He subsequently joined Chiron as VP and Clinical Director Europe. He was involved in the set-up of the EU part of the company and the successful MAA of Cubicin. He left over two years later when Novartis absorbed Chiron. In May 2007 he joined Viropharma as VP Clinical Director Europe and was involved in the setup of the EU company and the EU transplant maribivir phase 3 studies.

Richard has been a member of various working parties of the BSAC, ESCMID, European Union Grant Committee, EFPIA, IFPMA, EMA guidelines, Wellcome Trust, Medical Research Council, Surgical Infection Society (US) and the working party of the WHO on Bacterial Resistance as well as a consultant to the office of AIDS Research NIH US.

Richard has been a non-executive director of three start-up pharma companies.

Richard Bax is involved in guiding companies through early development, Phase I, II and III including Proof of Concept, to successful registration and to manage difficult strategic and scientific issues.

Richard Bax’s major activity is to bridge the gap between the company and the regulatory and reimbursement agencies.

Richard has over 100 publications, including nine book chapters and in peer reviewed journals including the BMJ, The Lancet, New England Journal of Medicine, Nature Medicine and Nature New Drugs on clinical trials, antibiotic resistance and prescribing, PK/PD predictors of outcome and the Pharmaceutical Industry.